Maridebart Cafraglutide (MariTide)
Awaiting review, BioHarmony verdict
Not yet scored. Queued for review; until then rely on the status and sources below.
What is Maridebart Cafraglutide (MariTide)?
Amgen describes MariTide (maridebart cafraglutide) as an investigational antibody-peptide conjugate in an ongoing phase 3 obesity program.
Saved on this device only.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for Maridebart Cafraglutide (MariTide) yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
US approvalInvestigational
CompoundingNo FDA-approved product; compounding eligibility is not established
Primary sources
- Amgen 2025 full-year pipeline update Amgen,
- MARITIME-1: phase 3 study of maridebart cafraglutide for chronic weight management ClinicalTrials.gov, U.S. National Library of Medicine,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.